Strategic partnerships MeMed actively partners with distributors and regional players (e.g., AB Scientific) to accelerate adoption of its BV test across the UK & Ireland, presenting an opportunity to propose regional deployment and co-marketing collaborations with new distributors or healthcare networks.

Expanded diagnostic reach Recent news highlights progress toward rapid, finger-prick based differentiation of bacterial versus viral infections, signaling a shift toward point-of-care diagnostics; sales pitches can emphasize ease of use, reduced turnaround, and potential integration with telehealth platforms.

Board leadership momentum New appointments to MeMed’s board in 2023-2024 suggest strategic governance and growth initiatives; potential entry points include executive roundtables, advisory roles, and pilot programs aligned with leadership vision.

Walmart telehealth footprint Walmart’s 2021 acquisition of MeMed’s telehealth capabilities indicates a scalable channel through retail health services; explore expansions or white-label partnerships within large employer clinics, retail health corridors, and telemedicine networks.

Scale and funding signals With significant revenue and external funding, MeMed is positioned for expansion in clinical adoption and global markets; opportunities exist for collaboration on large-scale deployments, hospital system integrations, and payer-aligned rollout strategies.